Pain intensity at presentation is a survival predictor in head and neck cancer
the ONA take:
Pain is the most significant side effect of cancer and its treatments. Researchers at M.D. Anderson Cancer Center assessed the extent to which pain severity influenced prognosis in 2,340 patients with newly diagnosed head and neck cancer.
They found pain severity to be an independent predictor of survival among patients with oral cancer. Squamous cell cancer is the most prevalent head and neck cancer, which includes cancers of the oral cavity, tongue, pharynx, and larynx. Pain occurs in these cancers as a first sign of disease, due to the direct involvement of tissue and bone, as well as a result of treatments such as surgery, chemotherapy, and radiation.
In this assessment, patients were asked to rate their pain on a scale of 0 (no pain) to 10 (“pain as bad as you can imagine”) at first presentation. Severe pain was reported by 19% of patients, and was most prevalent in patients with oral cancer. Survival time was calculated from diagnosis to death or last follow-up. Overall, 5-year survival was higher among patients with oral cancer who did not report severe pain. Similar results were seen among patients with pharyngeal cancer, as well.
The researchers conclude that severe pain at presentation is a significant factor in patients with head and neck cancer, and pain should be assessed and promptly treated.
Researchers assessed the extent to which pain severity influenced prognosis.
Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society. Researchers at M.D. Anderson Cancer Center assessed the extent to which pain severity influences survival in 2,340 newly diagnosed patients with head and neck cancer.
At first presentation, patients rated their pain using a scale in which 0 meant no pain and 10 indicated "pain as bad as you can imagine." Survival time was calculated from diagnosis to death or last follow-up.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|